Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Elamipretide

A precedent for mitochondrial peptide therapeutics within a defined rare disease indication.

Conceptual three-dimensional molecular signature for Elamipretide; not an exact chemical structure.
Mitochondrial cardiolipin binding peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA accelerated approval for a defined rare disease indication

MHRA / UK LICENCE

No UK marketing authorisation identified

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access identified

PRIVATE LAWFUL USE CONTEXT

US approval does not create a lawful UK licensed longevity indication

EVIDENCE MATURITY

Accelerated approval with a confirmatory study requirement

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Emerging

PROFESSIONAL RELEVANCE

Do not treat this mitochondrial approval as validation of broad longevity claims around unrelated peptides.

Product, formulation and indication

Forzinity

US · Injection

Barth syndrome

Status history

Production baseline verification recorded.

FDA accelerated approval for Barth syndrome

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.